Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria.
about
Artesunate versus quinine for treating severe malariaYeast model uncovers dual roles of mitochondria in action of artemisinin.Purified E255L Mutant SERCA1a and Purified PfATP6 Are Sensitive to SERCA-type Inhibitors but Insensitive to ArtemisininsArtemisinin Resistance in Plasmodium falciparum MalariaHaem-activated promiscuous targeting of artemisinin in Plasmodium falciparumArtemether for severe malariaArtesunate versus quinine for treating severe malariaArtesunate versus quinine for treating severe malariaTherapeutic responses to different antimalarial drugs in vivax malariaClinical and parasitological response to oral chloroquine and primaquine in uncomplicated human Plasmodium knowlesi infectionsArtesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trialPharmacokinetic and pharmacodynamic considerations in antimalarial dose optimizationMaking the most of clinical data: reviewing the role of pharmacokinetic-pharmacodynamic models of anti-malarial drugsArtemisinins: their growing importance in medicineetramps, a new Plasmodium falciparum gene family coding for developmentally regulated and highly charged membrane proteins located at the parasite-host cell interfaceThe Plasmodium falciparum translationally controlled tumor protein homolog and its reaction with the antimalarial drug artemisininLarge-scale differential proteome analysis in Plasmodium falciparum under drug treatmentInhibition of Plasmepsin V activity demonstrates its essential role in protein export, PfEMP1 display, and survival of malaria parasitesSevere falciparum malaria. World Health Organization, Communicable Diseases ClusterHigh-throughput analysis of antimalarial susceptibility data by the WorldWide Antimalarial Resistance Network (WWARN) in vitro analysis and reporting tool.Stage independent chloroquine resistance and chloroquine toxicity revealed via spinning disk confocal microscopy.The binding modes and binding affinities of artemisinin derivatives with Plasmodium falciparum Ca2+-ATPase (PfATP6).The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread.Resistance to antimalarial drugs: molecular, pharmacologic, and clinical considerations.Untargeted Proteomics and Systems-Based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells.Combinations of artemisinin and quinine for uncomplicated falciparum malaria: efficacy and pharmacodynamics.Assessment of three in vitro tests and an in vivo test for chloroquine resistance in Plasmodium falciparum clinical isolates.Artemisinin drugs: novel antimalarial agents.Oral artesunate dose-response relationship in acute falciparum malariaMitochondrial electron transport inhibition and viability of intraerythrocytic Plasmodium falciparum.Altered temporal response of malaria parasites determines differential sensitivity to artemisininTreating severe malaria in pregnancy: a review of the evidenceIntrahost modeling of artemisinin resistance in Plasmodium falciparumThe effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in South sumatra, Western indonesia: an open-label, randomized, controlled trial.Artemisone uptake in Plasmodium falciparum-infected erythrocytes.Population kinetics, efficacy, and safety of dichloroacetate for lactic acidosis due to severe malaria in children.Plasmodium drug targets outside the genetic control of the parasite.In vivo parasitological measures of artemisinin susceptibilityModelling the time course of antimalarial parasite killing: a tour of animal and human models, translation and challengesAcquired resistance of malarial parasites against artemisinin-based drugs: social and economic impacts.
P2860
Q21032520-1856E077-266A-4445-802A-DFD0BFCE5A18Q21145281-F4D63D35-F2F1-4E9E-8BA7-CFD721514119Q22061846-E3AE5DCF-EBD5-4D49-917E-579D34108093Q22061852-D5FBA692-4B41-4A4B-A62E-FC846A799E6BQ22061870-F4CD63E2-46CC-4584-A2BC-327EBA8DF90EQ24193663-C364C342-444B-4436-AE36-CC03EE3FC52CQ24235937-7803C601-15D1-460A-A199-E0FCBB93C6C8Q24242928-EC0DE084-CD1E-4E9D-B2EE-3C794C77156BQ24550626-A571F4FD-6A96-4A86-A265-C561CADBBF9AQ24617466-B867CC70-593D-408E-A74D-3989F41CAABAQ24630683-55DEC533-0795-48D6-A4AF-10BB5E090377Q26830528-A472613A-7B47-4067-AD50-70CEC9F36BA1Q27025529-C0CC9BCF-C459-4969-A7AD-B49C90FA6825Q27489880-9CC78FA9-B1B4-4DB6-90A6-47898E3BCFCFQ27972823-02EA980E-F830-4B2C-8B3B-919EE52EBFB0Q28274190-E700C354-33A4-493F-BEEE-1AA1922722A7Q28474424-22024EC1-32B9-4AAD-BB10-BD774E87F134Q28540204-F854E905-3270-4F88-AAF9-610D9F296A33Q29614923-C2152618-F67E-4548-8BD9-1B5FC66FEF88Q30619647-AF600B7F-935B-4964-8440-24B398CB82C4Q33320129-CCF5960F-DAD7-4CD0-BD93-3188EFB395F6Q33576032-9F12EE2B-3787-422D-8782-E864484AD993Q33655603-7CA090D0-17E8-41F9-A918-DD5D6CA6A548Q33723453-49249580-F71E-4585-9D4A-37F517044001Q33824170-53B70D63-5944-46CF-BEF3-E41B46E4D9BDQ33979461-B6F4889B-884A-427A-8D39-1C3D74DF1F4CQ34073271-706342AD-F056-4607-8460-49BB54AC7878Q34075018-79836F94-9192-4A9C-B056-CDF918177EB2Q34113505-357A4182-A5AE-4FDB-9AEA-CBFEE2238D44Q34309434-23990BBE-6BA0-4F53-9F6B-60D1B7A4A30CQ34329125-D2318A72-5B58-4B3C-B4CC-8B92755E2275Q34456393-A650D4C3-6733-4499-B615-3850415AC140Q34471842-9126D91F-6259-46AA-9499-E56784B1083DQ34486508-C0443AF5-459B-40A3-BF3C-0602122B2126Q34529331-4D5D093F-C668-473D-8B42-1DF1F0FC1D4FQ34533270-ECB4C580-3418-4921-8477-377097313DD2Q34678568-53DB8F3C-D56A-4E0C-9DE2-AFAF2BE3A7CCQ34921155-D53BDEF9-CB7C-4E71-87A4-C38545CACEC4Q34953705-A4ACBA26-AA2E-4FFA-82BE-443946740E8AQ35026586-25259EDB-689A-4F87-9BA3-6C2A80151260
P2860
Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Plasmodium falciparum: in vitr ...... e treatment of severe malaria.
@en
Plasmodium falciparum: in vitr ...... e treatment of severe malaria.
@nl
type
label
Plasmodium falciparum: in vitr ...... e treatment of severe malaria.
@en
Plasmodium falciparum: in vitr ...... e treatment of severe malaria.
@nl
prefLabel
Plasmodium falciparum: in vitr ...... e treatment of severe malaria.
@en
Plasmodium falciparum: in vitr ...... e treatment of severe malaria.
@nl
P50
P356
P1476
Plasmodium falciparum: in vitr ...... e treatment of severe malaria.
@en
P2093
P356
10.1006/EXPR.1993.1010
P577
1993-02-01T00:00:00Z